Atossa Therapeutics, Inc. Stock price

Equities

ATOS

US04962H5063

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.8 USD -1.64% Intraday chart for Atossa Therapeutics, Inc. +7.14% +104.55%
Sales 2023 * - Sales 2024 * - Capitalization 226M
Net income 2023 * -30M Net income 2024 * -32M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-7.5 x
P/E ratio 2024 *
-6.92 x
Employees 11
Yield 2023 *
-
Yield 2024 *
-
Free-Float 98.92%
More Fundamentals * Assessed data
Dynamic Chart
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient CI
Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors CI
Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment CI
Atossa Therapeutics Rises After HC Wainwright Starts Coverage with Buy Rating MT
HC Wainwright Initiates Atossa Therapeutics With Buy Rating, Price Target is $4 MT
Atossa Therapeutics, Inc. Announces Full Enrollment of (Z) -Endoxifen Arm of I-Spy 2 Clinical Trial CI
Atossa Therapeutics, Inc.'s Equity Buyback announced on June 27, 2023, has expired with 1,320,046 shares, representing 1.04% for $1.44 million. CI
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director CI
Atossa Therapeutics Says Full Enrollment Reached in Karisma-Endoxifen Trial of Breast-Cancer Drug MT
Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial CI
Tranche Update on Atossa Therapeutics, Inc.'s Equity Buyback Plan announced on June 27, 2023. CI
Atossa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors CI
North American Morning Briefing : Investors Weigh -2- DJ
Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors CI
More news
1 day-1.64%
1 week+7.14%
Current month+84.24%
1 month+80.00%
3 months+84.41%
6 months+138.41%
Current year+104.55%
More quotes
1 week
1.61
Extreme 1.61
1.94
1 month
0.98
Extreme 0.98
1.94
Current year
0.77
Extreme 0.7744
1.94
1 year
0.59
Extreme 0.5901
1.94
3 years
0.50
Extreme 0.5
9.80
5 years
0.50
Extreme 0.5
9.80
10 years
0.50
Extreme 0.5
477.00
More quotes
Managers TitleAgeSince
Founder 62 08-11-30
Chief Executive Officer 73 08-11-30
Chief Tech/Sci/R&D Officer - Dec. 03
Members of the board TitleAgeSince
Chief Executive Officer 73 08-11-30
Director/Board Member 66 14-02-28
Director/Board Member 72 12-01-31
More insiders
Date Price Change Volume
24-03-28 1.8 -1.64% 1,890,373
24-03-27 1.83 +1.67% 2,548,777
24-03-26 1.8 -4.76% 3,789,850
24-03-25 1.89 +13.17% 3,230,483
24-03-22 1.67 -0.60% 1,869,631

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines in areas of unmet medical need in oncology with a focus on breast cancer. The Company's lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. It is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.8 USD
Average target price
4.583 USD
Spread / Average Target
+154.63%
Consensus
  1. Stock
  2. Equities
  3. Stock Atossa Therapeutics, Inc. - Nasdaq